Report Sections

See All Reports

  • HP:0012819: Myocarditis
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0012819: Myocarditis

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (18)


    Name (Synonyms) Correlation
    drug2447 Performing routine care (clinical and paraclinical tests) Wiki 0.35
    drug699 Capillary and salivary sampling Wiki 0.35
    drug710 Cardiovascular Magnetic Resonance (CMR) Imaging Wiki 0.35
    Name (Synonyms) Correlation
    drug2413 Passed infection of SARS-CoV-2 Wiki 0.35
    drug1163 Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care Wiki 0.35
    drug3948 muscle ultrasound Wiki 0.35
    drug3904 laboratory biomarkers Wiki 0.35
    drug3475 Transthoracic echocardiogram (TTE) Wiki 0.35
    drug1225 Examinations for the research: Wiki 0.35
    drug1822 LifeSignals Biosensor 1AX* Wiki 0.35
    drug489 Blood samples (collection of 5 mL of blood in a dry tube) Wiki 0.35
    drug2154 Nasopharyngeal swabs Wiki 0.25
    drug58 50 mg/mL Virazole Wiki 0.25
    drug3323 Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling. Wiki 0.25
    drug445 Biological data Wiki 0.25
    drug25 100 mg/mL Virazole Wiki 0.25
    drug784 Clinical data Wiki 0.20
    drug3191 Standard of Care Wiki 0.05

    Correlated MeSH Terms (20)


    Name (Synonyms) Correlation
    D009205 Myocarditis NIH 1.00
    D018376 Cardiovascular Abnormalities NIH 0.35
    D009220 Myositis NIH 0.25
    Name (Synonyms) Correlation
    D006330 Heart Defects, Congenital NIH 0.25
    D009203 Myocardial Ischemia NIH 0.20
    D018754 Ventricular Dysfunction NIH 0.18
    D001145 Arrhythmias, Cardiac NIH 0.18
    D054058 Acute Coronary Syndrome NIH 0.18
    D018487 Ventricular Dysfunction, Left NIH 0.18
    D006331 Heart Diseases NIH 0.13
    D007238 Infarction NIH 0.12
    D054556 Venous Thromboembolism NIH 0.12
    D020246 Venous Thrombosis NIH 0.11
    D011655 Pulmonary Embolism NIH 0.09
    D004617 Embolism NIH 0.09
    D013923 Thromboembolism NIH 0.08
    D013927 Thrombosis NIH 0.07
    D018352 Coronavirus Infections NIH 0.02
    D007239 Infection NIH 0.02
    D045169 Severe Acute Respiratory Syndrome NIH 0.01

    Correlated HPO Terms (8)


    Name (Synonyms) Correlation
    HP:0001627 Abnormal heart morphology HPO 0.25
    HP:0100614 Myositis HPO 0.25
    HP:0001658 Myocardial infarction HPO 0.20
    Name (Synonyms) Correlation
    HP:0011675 Arrhythmia HPO 0.18
    HP:0002625 Deep venous thrombosis HPO 0.11
    HP:0002204 Pulmonary embolism HPO 0.09
    HP:0001907 Thromboembolism HPO 0.07
    HP:0001626 Abnormality of the cardiovascular system HPO 0.06

    Clinical Trials

    Navigate: Correlations   HPO

    There are 8 clinical trials


    1 Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19

    COVID-19 outbreak is often lethal. Mortality has been associated with several cardio-vascular risk factors such as diabetes, obesity, hypertension and tobacco use. Other clinico-biological features predictive of mortality or transfer to Intensive Care Unit are also needed. Cases of myocarditis have also been reported with COVID-19. Cardio-vascular events have possibly been highly underestimated. The study proposes to systematically collect cardio-vascular data to study the incidence of myocarditis and coronaropathy events during COVID-19 infection.We will also assess predictive factors for transfer in Intensive Care Unit or death.

    NCT04320017
    Conditions
    1. COVID-19
    2. Myocardial Injury
    3. Myocarditis
    Interventions
    1. Diagnostic Test: Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care
    MeSH:Myocarditis
    HPO:Myocarditis

    Primary Outcomes

    Description: Viral myocarditis or myocardial infarction or stenosis detected with ST segment elevation or depression associated with troponine elevation and transthoracic echocardiography

    Measure: Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay

    Time: ECG and concomitant troponine at day 1 after admission at day 1, day 3 day 6 the first week after admission, and then at day 14 and before the patient is discharged (up to 20 days)

    Secondary Outcomes

    Description: Cardio-vascular events including but not limited to: myocardial infarction or stenosis, stroke, pulmonary embolism, deep vein thrombosis, ventricular dysfunctio, conduction disorders and sudden death

    Measure: Description of cardiovascular outcomes in the cohort

    Time: During hospital admission (up to 20 days)

    Description: Biological biomarkers including but not limited to: baseline troponine T, D-dimers, NT-proBNP, creatinine phosphokinase, creatininemia, ionogram, renine-angiotensin aldosterone system profiling, glycemia (fasting), HbA1c, steroid profiling, lipid profiling

    Measure: Prognosis role of baseline cardio-vascular caracteristics on patients survival

    Time: 1st day of admission

    Measure: Prediction of cardio-vascular events with baseline characteristics

    Time: Baseline on first day of admission

    Description: Biological markers including but not limited to: C reactive protein, procalcitonine, fibrinogen, interleukin-6

    Measure: Characterization of inflammation on cardio-vascular outcomes

    Time: Baseline and at day 3 day 6 day 14 and before patient is discharged (up to 20 days)

    Description: clinical features at baseline: WHO performans status comorbidities and treatments Biological markers including but not limited to: full blood count, C reactive protein, procalcitonine, fibrinogen, interleukin-6, troponin and brain natriuretic peptide

    Measure: Prognosis role of baseline clinico-biological caracteristics on patients transfer to ICU and survival

    Time: Baseline and at day 3 day 6 day 14 and before patient is discharged (up to 20 days)
    2 Cardiovascular Complications in Patients With COVID-19

    Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.

    NCT04335162
    Conditions
    1. COVID
    2. Acute Coronary Syndrome
    3. Myocardial Infarction
    4. Myocarditis
    5. Venous Thromboembolism
    6. Deep Vein Thrombosis
    7. Pulmonary Embolism
    MeSH:Pulmonary Embolism Myocardial Infarction Thrombosis Acute Coronary Syndrome Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis Myocarditis
    HPO:Deep venous thrombosis Myocardial infarction Myocarditis Pulmonary embolism Thromboembolism Venous thrombosis

    Primary Outcomes

    Description: Incidence of cardiomyopathies and/or venous thromboembolism at day 28

    Measure: Determine the incidence of cardiomyopathies and venous thromboembolism

    Time: 28 days

    Secondary Outcomes

    Description: Incidence of mortality at day 28

    Measure: Mortality

    Time: 28 days

    Description: Number of day of using mechanical ventilation for each patients

    Measure: Duration of mechanical ventilation

    Time: hospitalisation duration

    Description: Incidence of shock during hospitalisation

    Measure: Shock

    Time: hospitalisation duration

    Description: Number of day at hospital

    Measure: length of stay

    Time: hospitalisation duration

    Description: Setting up or not of mechanical ventilation

    Measure: Mechanical ventilation

    Time: hospitalisation duration

    Description: Administration or not of renal replacement therapy

    Measure: Renal replacement therapy

    Time: hospitalisation duration
    3 Prospective Registry for Multimodal Assessment of Neuromuscular Pathology Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

    Prospective registry for multimodal assessment of neuromuscular pathology associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, enrolling consecutive patients with corona virus disease 2019 (Covid-19), who are admitted to the intensive care unit of the department of anesthesiology and intensive care medicine, or the department of neurology at Tübingen University Hospital.

    NCT04367350
    Conditions
    1. COVID
    2. Sars-CoV2
    3. Corona Virus Infection
    4. Myositis
    5. Myocarditis
    Interventions
    1. Diagnostic Test: laboratory biomarkers
    2. Diagnostic Test: muscle ultrasound
    MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome Myositis Myocarditis
    HPO:Inflammatory myopathy Myocarditis Myositis

    Primary Outcomes

    Description: Elevation of creatine kinase during hyperacute phase of corona virus disease 2019 (Covid-19)

    Measure: Rate of elevated creatine kinase in hyperacute phase

    Time: 1 week

    Secondary Outcomes

    Description: Elevation of creatine kinase during hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)

    Measure: Rate of elevated creatine kinase

    Time: 24 months

    Description: Two-peak elevation of creatine kinase during acute phase of corona virus disease 2019 (Covid-19)

    Measure: Rate of two-peak elevation of creatine kinase during acute phase

    Time: 30 days

    Description: Presence of myositis-specific antibodies on admission, at two weeks, and at end of follow-up

    Measure: Rate of myositis-specific antibodies

    Time: 24 months

    Description: Presence of antimyocardial antibodies on admission, at two weeks, and at end of follow-up

    Measure: Rate of antimyocardial antibodies

    Time: 24 months

    Description: Level of creatine kinase elevation in the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19) assessed by the area under the curve (AUC)

    Measure: Area under the curve (AUC) of elevated creatine kinase

    Time: 24 months

    Description: Maximal value of creatine kinase elevation in the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)

    Measure: Peak-levels of elevated creatine kinase

    Time: 24 months

    Description: Maximal value of troponin in the acute phase of corona virus disease 2019 (Covid-19)

    Measure: Peak-levels of troponin

    Time: 30 days

    Description: Maximal value of urine myoglobin in the acute of corona virus disease 2019 (Covid-19)

    Measure: Peak-levels of urine myoglobin

    Time: 30 days

    Description: Muscle hyperechogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score) during the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)

    Measure: Rate of muscle hyperechogenicity

    Time: 24 months

    Description: Peak-muscle hyperechogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score) during the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)

    Measure: Peak-muscle hyperechogenicity

    Time: 24 months
    4 Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 Cases During the Covid-19 Pandemic, Case Characteristics and Prognoses

    To date, the effects of SARS-Cov-2 (Covid-19) on the myocardium and the role it plays in the evolution towards an acute myocarditis are badly understood. The current pandemic of this emerging virus is an opportunity to assess the proportion of acute myocarditis attributable to SARS-Cov-2(Covid-19) and to assess the clinical, biological and imaging presentations, by means of a national prospective multicentre hospital registry of cases of acute myocarditis.

    NCT04375748
    Conditions
    1. Acute Myocarditis
    Interventions
    1. Diagnostic Test: Performing routine care (clinical and paraclinical tests)
    2. Diagnostic Test: Examinations for the research:
    MeSH:Myocarditis
    HPO:Myocarditis

    Primary Outcomes

    Description: Estimate at hospital discharge, over a period of 6 months, the evolution of the proportion of positive SARS-COV-2 cases among patients hospitalized for acute myocarditis in Intensive Cardiac Care Unit or Intensive Care Unit (polyvalent, surgical or medical), in the 19 hospitals participating in the study.

    Measure: Evolution of the proportion of positive SARS-COV-2 cases.

    Time: 6 months.

    Secondary Outcomes

    Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort; Echocardiographic parameters: Volumes (mm3)

    Measure: Ultrasound characteristics.

    Time: 1 year

    Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: diameters (mm)

    Measure: Ultrasound characteristics.

    Time: 1 year

    Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort (Echocardiographic parameters: ventricular diastolic function (mm);

    Measure: Ultrasound characteristics.

    Time: 1 year

    Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort (Echocardiographic parameters: ventricular systolic function (mm);

    Measure: Ultrasound characteristics.

    Time: 1 year

    Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Left atrium volume (mm3);

    Measure: Ultrasound characteristics.

    Time: 1 year

    Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Maximum velocity of tricuspid valve insufficiency;

    Measure: Ultrasound characteristics.

    Time: 1 year

    Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Presence and quantification of a valvular regurgitation

    Measure: Ultrasound characteristics.

    Time: 1 year

    Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Presence of a pericardial effusion

    Measure: Ultrasound characteristics.

    Time: 1 year

    Description: Assess the short-term (30 days) and long-term (1 year) prognosis of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort. The 30-day prognosis will be defined in function to the outcome: A death, whatever the cause, A cardiovascular arrest with recovery, A cardiogenic shock, An acute lung oedema or One of the events cited above. The 1-year prognosis will be defined in function to the outcome: A death, whatever the cause, The need to resort to transplantation and/or chronic assistance, A rehospitalization for cardiovascular reasons (heart failure, painful relapse, recovered cardiac arrest, myocarditis relapse, ACS), A myocarditis relapse, or one of the events cited above. The 1-year prognosis will also be defined in function to the New York Heart Association (NYHA) class.

    Measure: Assess prognosis of the acute myocarditis .

    Time: The short-term (30 days) and long-term (1 year).

    Description: Identify the factors associated with a 30-day and 1-year prognosis of cases of acute myocarditis cardiovascular (Terminal heart failure, Acute edema of the lung, Cardiogenic shock, Sudden death / Ventricular rhythm disorder Pulmonary embolism, Aortic dissection Infectious endocarditis Stroke) or no cardiovascular (Acute respiratory syndrome, septic shock of non-cardiac origin, cancer, Public road accident, end-stage respiratory failure, insufficiency, end-stage renal Failure)

    Measure: The factors associated with acute myocarditis cases .

    Time: The short-term (30 days) and long-term (1 year).

    Description: Describe the biological parameters on admission and during the treatment (troponinemia (ng/ml)

    Measure: Biological characteristics

    Time: 1 year

    Description: Describe the biological parameters on admission and during the treatment NtproBNP(pg/ml)

    Measure: Biological characteristics

    Time: 1 year

    Description: Describe the biological parameters on admission and during the treatment CRP(mg/ml)

    Measure: Biological characteristics

    Time: 1 year

    Description: Ventricular volumes (ml)

    Measure: Describe at the admission and during the treatment cardiac MRI parameters

    Time: 1 year

    Description: Systole Diameter

    Measure: Describe at the admission and during the treatment cardiac MRI parameters

    Time: 1 year

    Description: Diastole Diameter

    Measure: Describe at the admission and during the treatment cardiac MRI parameters

    Time: 1 year

    Description: Longitudinal deformation of left ventricle;

    Measure: Describe at the admission and during the treatment cardiac MRI parameters

    Time: 1 year

    Description: Longitudinal deformation of right ventricle;

    Measure: Describe at the admission and during the treatment cardiac MRI parameters

    Time: 1 year

    Description: Total volume of left ventricular oedema

    Measure: Describe at the admission and during the treatment cardiac MRI parameters

    Time: 1 year

    Description: Quantification of T2 before contrast agent

    Measure: Describe at the admission and during the treatment cardiac MRI parameters

    Time: 1 year

    Description: Quantification of T1 before contrast agent

    Measure: Describe at the admission and during the treatment cardiac MRI parameters

    Time: 1 year

    Description: Perfusion anomalies

    Measure: Describe at the admission and during the treatment cardiac MRI parameters

    Time: 1 year

    Description: Total volume of early left ventricular alteration

    Measure: Describe at the admission and during the treatment cardiac MRI parameters

    Time: 1 year

    Description: Total volume of late left ventricular alteration

    Measure: Describe at the admission and during the treatment cardiac MRI parameters

    Time: 1 year

    Description: Quantification of T1 after contrast agent

    Measure: Describe at the admission and during the treatment cardiac MRI parameters

    Time: 1 year

    Description: Presence of a pericardial effusion

    Measure: Describe at the admission and during the treatment cardiac MRI parameters

    Time: 1 year
    5 Cardiac Involvement in Coronavirus (SARS-Cov-2) Infected Health Care Workers: The CCC Study

    The study will analyze the prevalence of cardiac involvement of health care workers from the University Hospital of Salamanca (HUSA) who have overcome SARS-CoV-2 infection. Participants will undergo a clinical evaluation, electrocardiogram (EKG), cardiac magnetic resonance (CMR) and blood analysis including NT-proBNP, troponin, cellular and humoral immunity and genetics.

    NCT04413071
    Conditions
    1. SARS-CoV 2
    2. COVID-19
    3. Coronavirus
    4. Cardiac Magnetic Resonance
    5. Myocarditis
    6. Cardiac Anomaly
    Interventions
    1. Other: Passed infection of SARS-CoV-2
    MeSH:Coronavirus Infections Myocarditis Heart Defects, Congenital Cardiovascular Abnormalities
    HPO:Abnormal heart morphology Abnormality of the cardiovascular system Myocarditis

    Primary Outcomes

    Description: Prevalence of myocardial damage suggestive of myocarditis assessed by cardiac magnetic resonance

    Measure: Myocarditis

    Time: up to 3 months

    Description: Prevalence of pericarditis assessed by clinical criteria

    Measure: Pericarditis

    Time: up to 3 months

    Secondary Outcomes

    Description: Prevalence of atrial fibrillation on EKG

    Measure: Atrial fibrillation

    Time: up to 3 months

    Description: Prevalence of ischemic heart disease assessed by cardiac magnetic resonance

    Measure: Ischemic heart disease

    Time: up to 3 months

    Description: Prevalence of dilatation of right heart chambers assessed by cardiac magnetic resonance

    Measure: Dilatation of right heart chambers

    Time: up to 3 months

    Description: Prevalence of valvular heart disease assessed by cardiac magnetic resonance

    Measure: Valvular hear disease

    Time: up to 3 months

    Description: Prevalence of prolonged QT interval on EKG

    Measure: Rhythm disorders

    Time: up to 3 months
    6 Descriptive and Retrospective Analysis of Acute Myocarditis Associated With Pandemic COVID-19 in Children

    The study objectives are to descript clinical, biological and echocardiographic features of an acute myocarditis in children in the context of COVID-19 and to identify the underlying mechanism : direct viral damage and/or inadequate host response risk.

    NCT04420468
    Conditions
    1. COVID-19
    MeSH:Myocarditis
    HPO:Myocarditis

    Primary Outcomes

    Description: Occurrence, description and time course of acute myocarditis

    Measure: Acute myocarditis

    Time: 7 days

    Description: Occurrence, description and time course of multi-systemic inflammatory syndrome, features of Kawasaki disease

    Measure: Multi-systemic inflammatory syndrome

    Time: 7 days

    Description: Occurrence, description and time course of features of Kawasaki disease

    Measure: Kawasaki disease

    Time: 7 days

    Secondary Outcomes

    Description: Results of SARS-CoV-2 screening either by PCR or antibodies serological assay

    Measure: Results of SARS-CoV-2

    Time: 7 days
    7 MYocardial DOmmages Related to COVID-19

    Myocardial injury, as assessed by elevation of cardiac troponins (Tnc), is frequent among patients with COVID-19. Although rare autopsy cases reported COVID-19 related myocardial inflammation, the origin of Tnc elevation is unknown to date. Several cardiac causes, such as myocarditis, non-ischemic myocardial injury (NIMI), or myocardial infarction (MI) may lead to Tnc kinetic. Our work will test the hypothesis that during SARS-Cov2 infection, the elevation of cardiac biomarkers could be linked to the occurrence of myocarditis.

    NCT04498065
    Conditions
    1. Covid19
    2. Non Ischemic Myocardial Injury
    3. Myocardial Infarction
    4. Myocarditis
    5. Troponin Elevation
    Interventions
    1. Biological: Biological data
    2. Other: Clinical data
    MeSH:Myocardial Infarction Myocarditis Infarction
    HPO:Myocardial infarction Myocarditis

    Primary Outcomes

    Description: Myocardtitis diagnosis in patients COVID+ and troponin+

    Measure: characterize the myocardial damage associated with CoV-2 SARS infection

    Time: Through study completion, an average of 1 year
    8 COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae (COLUMBIA CARDS) Registry

    COLUMBIA CARDS is a pilot study to understand how COVID-19 affects the heart. It is known that COVID-19 can affect the heart in different ways. COLUMBIA CARDS is studying why some COVID-19 survivors develop clinical conditions such as heart inflammation, fluid buildup, blood clots, and other cardiac problems during or after their COVID-19 illness, and why other ones do not. In this study, we will use cardiovascular magnetic resonance (CMR) and transthoracic echocardiography (TTE) to better understand the impact of COVID-19 on the heart.

    NCT04661657
    Conditions
    1. Covid19
    2. Cardiac Disease
    3. Cardiac Arrhythmia
    4. Myocarditis
    5. Left Ventricular Dysfunction
    Interventions
    1. Other: Transthoracic echocardiogram (TTE)
    2. Other: Cardiovascular Magnetic Resonance (CMR) Imaging
    MeSH:Arrhythmias, Cardiac Ventricular Dysfunction Heart Diseases Ventricular Dysfunction, Left Myocarditis
    HPO:Arrhythmia Myocarditis

    Primary Outcomes

    Description: Percentage of myocardium demonstrating late gadolinium enhancement by cardiac magnetic resonance (CMR) imaging, determined using Circle cvi42 software.

    Measure: Percentage of myocardium demonstrating late gadolinium enhancement

    Time: Up to 2 hours

    Description: Extracellular volume fraction measured by CMR imaging. ECV determined using Circle cvi42 software and using formula ECV = (1-hematocrit) × (Δ(1/T1myocardium)/Δ(1/T1blood)).

    Measure: Extracellular Volume (ECV) Fraction

    Time: Up to 2 hours

    Description: Left ventricular ejection fraction (percent ejection fraction) by CMR imaging and determined using Circle cvi42 software.

    Measure: Left Ventricular Ejection Fraction

    Time: Up to 2 hours

    HPO Nodes


    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    Reports

    Data processed on January 01, 2021.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook